BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP decreased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 21.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 285,588 shares of the biotechnology company's stock after selling 78,250 shares during the quarter. GSA Capital Partners LLP owned 0.14% of BioCryst Pharmaceuticals worth $2,170,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioCryst Pharmaceuticals by 13.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 138,074 shares of the biotechnology company's stock worth $701,000 after purchasing an additional 15,894 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth approximately $327,000. Inspire Investing LLC raised its holdings in shares of BioCryst Pharmaceuticals by 9.7% during the first quarter. Inspire Investing LLC now owns 69,466 shares of the biotechnology company's stock valued at $353,000 after purchasing an additional 6,141 shares during the last quarter. Russell Investments Group Ltd. lifted its position in BioCryst Pharmaceuticals by 200.8% during the first quarter. Russell Investments Group Ltd. now owns 58,725 shares of the biotechnology company's stock valued at $298,000 after purchasing an additional 39,205 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company's stock worth $246,000 after purchasing an additional 4,041 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on BCRX shares. Needham & Company LLC reissued a "buy" rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 5th. StockNews.com raised shares of BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, August 6th. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $14.67.

BioCryst Pharmaceuticals Trading Down 3.3 %

Shares of BCRX stock traded down $0.27 during trading hours on Tuesday, reaching $7.92. 384,336 shares of the company's stock were exchanged, compared to its average volume of 2,955,278. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -13.43 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The stock's 50 day moving average is $7.75 and its 200-day moving average is $7.07.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals's revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.19) earnings per share. Equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.